drugset
drugset / Trial / NCT01088906

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC

NCT01088906 ↗

Phase 2 Terminated 57 enrolled Spanish Lung Cancer Group
NaSingle-groupOpen-labelTreatment

Summary

This is a study of pemetrexed disodium plus cisplatin as first-line therapy in patients with advanced non-squamous cell lung cancer. This is a phase IIA pharmacogenomic trial.

Timeline

Start
2010-01
Primary completion
2014-04
Completion
2014-04

Outcome

Outcome not reported

Stopped (Enrollment): “No safety reasons. Low recruitment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma